Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer

Immune checkpoint (IC) blockade using monoclonal antibodies is currently one of the most successful immunotherapeutic interventions to treat cancer. By reinvigorating antitumor exhausted T cells, this approach can lead to durable clinical responses. However, the majority of patients either do not re...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossetti, Rafaela, Brand, Heloísa, Lima, Sarah Caroline Gomes, Furtado, Izadora Peter, Silveira, Roberta Maraninchi, Fantacini, Daianne Maciely Carvalho, Covas, Dimas Tadeu, de Souza, Lucas Eduardo Botelho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
T Cell-Targeted Approaches to Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327125/
https://www.ncbi.nlm.nih.gov/pubmed/35919489
http://dx.doi.org/10.1093/immadv/ltac005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327125/
https://www.ncbi.nlm.nih.gov/pubmed/35919489
http://dx.doi.org/10.1093/immadv/ltac005

Ejemplares similares